{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:20:19Z","timestamp":1761895219750},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T00:00:00Z","timestamp":1294963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s12185-010-0764-9","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T03:19:28Z","timestamp":1294888768000},"page":"186-191","source":"Crossref","is-referenced-by-count":13,"title":["Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era"],"prefix":"10.1007","volume":"93","author":[{"given":"Hideki","family":"Muramatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahito","family":"Hama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayoko","family":"Doisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimikazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,14]]},"reference":[{"key":"764_CR1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0031-3955(16)36509-9","volume":"35","author":"AJ Altman","year":"1988","unstructured":"Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am. 1988;35:765\u201387.","journal-title":"Pediatr Clin North Am"},{"key":"764_CR2","first-page":"819","volume":"50","author":"S Kojima","year":"1987","unstructured":"Kojima S, Yoshida J, Yoshikawa S, Iwamura H, Tonouchi T, Mimaya J. Philadelphia chromosome positive chronic myelocytic leukemia in children. Acta Haematol Jpn. 1987;50:819\u201327.","journal-title":"Acta Haematol Jpn."},{"key":"764_CR3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","volume":"102","author":"K Cwynarski","year":"2003","unstructured":"Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224\u201331.","journal-title":"Blood"},{"key":"764_CR4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","volume":"32","author":"F Millot","year":"2003","unstructured":"Millot F, Esperou H, Bordigoni P, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2003;32:993\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"764_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2008-1046479","volume":"208","author":"U Creutzig","year":"1996","unstructured":"Creutzig U, Ritter J, Zimmermann M, Klingebiel T. Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients. Klin Padiatr. 1996;208:236\u201341.","journal-title":"Klin Padiatr."},{"key":"764_CR6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","volume":"99","author":"DJ Weisdorf","year":"2002","unstructured":"Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971\u20137.","journal-title":"Blood"},{"key":"764_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","volume":"16","author":"H Muramatsu","year":"2010","unstructured":"Muramatsu H, Kojima S, Yoshimi A, et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2010;16:231\u20138.","journal-title":"Biol Blood Marrow Transplant."},{"key":"764_CR8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"764_CR9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u201332.","journal-title":"N Engl J Med"},{"key":"764_CR10","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","volume":"104","author":"MA Champagne","year":"2004","unstructured":"Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study. Blood. 2004;104:2655\u201360.","journal-title":"Blood"},{"key":"764_CR11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.leu.2404051","volume":"20","author":"F Millot","year":"2006","unstructured":"Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20:187\u201392.","journal-title":"Leukemia."},{"key":"764_CR12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","volume":"1","author":"B Speck","year":"1984","unstructured":"Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;1:665\u20138.","journal-title":"Lancet"},{"key":"764_CR13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"764_CR14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2009. http:\/\/ctepcancergov\/protocolDevelopment\/electronic_applications\/ctchtm#ctc_40 ."},{"key":"764_CR15","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513\u201321.","journal-title":"Haematologica"},{"key":"764_CR16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"764_CR17","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022\u20138.","journal-title":"Blood"},{"key":"764_CR18","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139.","journal-title":"Blood"},{"key":"764_CR19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109:58\u201360.","journal-title":"Blood"},{"key":"764_CR20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","volume":"33","author":"S Guastafierro","year":"2009","unstructured":"Guastafierro S, Falcone U, Celentano M, Coppola M, Ferrara MG, Sica A. Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature. Leuk Res. 2009;33:1079\u201381.","journal-title":"Leuk Res."},{"key":"764_CR21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.leukres.2008.04.018","volume":"33","author":"T Kiguchi","year":"2009","unstructured":"Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res. 2009;33:506\u20138.","journal-title":"Leuk Res."},{"key":"764_CR22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","volume":"89","author":"T Kimoto","year":"2009","unstructured":"Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol. 2009;89:251\u20132.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0764-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0764-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0764-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:01:37Z","timestamp":1559451697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0764-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,14]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0764-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,14]]}}}